These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. Optimizing treatment outcomes in HIV-infected patients with substance abuse issues. Celentano DD; Lucas G Clin Infect Dis; 2007 Dec; 45 Suppl 4():S318-23. PubMed ID: 18190306 [TBL] [Abstract][Full Text] [Related]
23. The interaction of active substance use, depression, and antiretroviral adherence in methadone maintenance. Newville H; Berg KM; Gonzalez JS Int J Behav Med; 2015 Apr; 22(2):214-22. PubMed ID: 25081100 [TBL] [Abstract][Full Text] [Related]
24. Crack-cocaine use accelerates HIV disease progression in a cohort of HIV-positive drug users. Baum MK; Rafie C; Lai S; Sales S; Page B; Campa A J Acquir Immune Defic Syndr; 2009 Jan; 50(1):93-9. PubMed ID: 19295339 [TBL] [Abstract][Full Text] [Related]
25. A comparison of exposure groups in the EuroSIDA study: starting highly active antiretroviral therapy (HAART), response to HAART, and survival. Mocroft A; Madge S; Johnson AM; Lazzarin A; Clumeck N; Goebel FD; Viard JP; Gatell J; Blaxhult A; Lundgren JD J Acquir Immune Defic Syndr; 1999 Dec; 22(4):369-78. PubMed ID: 10634199 [TBL] [Abstract][Full Text] [Related]
26. Adherence to HAART among HIV-infected persons in rural Louisiana. Mohammed H; Kieltyka L; Richardson-Alston G; Magnus M; Fawal H; Vermund SH; Rice J; Kissinger P AIDS Patient Care STDS; 2004 May; 18(5):289-96. PubMed ID: 15186712 [TBL] [Abstract][Full Text] [Related]
27. Gender differences in HIV-1 RNA rebound attributed to incomplete antiretroviral adherence among HIV-Infected patients in a population-based cohort. Kuyper LM; Wood E; Montaner JS; Yip B; O'connell JM; Hogg RS J Acquir Immune Defic Syndr; 2004 Dec; 37(4):1470-6. PubMed ID: 15602125 [TBL] [Abstract][Full Text] [Related]
28. A randomized clinical trial of community-based directly observed therapy as an adherence intervention for HAART among substance users. Macalino GE; Hogan JW; Mitty JA; Bazerman LB; Delong AK; Loewenthal H; Caliendo AM; Flanigan TP AIDS; 2007 Jul; 21(11):1473-7. PubMed ID: 17589194 [TBL] [Abstract][Full Text] [Related]
29. Failure to maintain adherence to HAART in a cohort of French HIV-positive injecting drug users. Carrieri MP; Chesney MA; Spire B; Loundou A; Sobel A; Lepeu G; Moatti JP; Int J Behav Med; 2003; 10(1):1-14. PubMed ID: 12581944 [TBL] [Abstract][Full Text] [Related]
30. Adherence to HAART in French HIV-infected injecting drug users: the contribution of buprenorphine drug maintenance treatment. The Manif 2000 study group. Moatti JP; Carrieri MP; Spire B; Gastaut JA; Cassuto JP; Moreau J AIDS; 2000 Jan; 14(2):151-5. PubMed ID: 10708285 [TBL] [Abstract][Full Text] [Related]
31. Drug use patterns associated with risk of non-adherence to antiretroviral therapy among HIV-positive illicit drug users in a Canadian setting: a longitudinal analysis. Azar P; Wood E; Nguyen P; Luma M; Montaner J; Kerr T; Milloy MJ BMC Infect Dis; 2015 Apr; 15():193. PubMed ID: 25927573 [TBL] [Abstract][Full Text] [Related]
32. Study of the impact of HIV genotypic drug resistance testing on therapy efficacy. Van Vaerenbergh K Verh K Acad Geneeskd Belg; 2001; 63(5):447-73. PubMed ID: 11813503 [TBL] [Abstract][Full Text] [Related]
33. Relationship of gender, depression, and health care delivery with antiretroviral adherence in HIV-infected drug users. Turner BJ; Laine C; Cosler L; Hauck WW J Gen Intern Med; 2003 Apr; 18(4):248-57. PubMed ID: 12709091 [TBL] [Abstract][Full Text] [Related]
34. Is the quality of the patient-provider relationship associated with better adherence and health outcomes for patients with HIV? Beach MC; Keruly J; Moore RD J Gen Intern Med; 2006 Jun; 21(6):661-5. PubMed ID: 16808754 [TBL] [Abstract][Full Text] [Related]
35. Factors associated with antiretroviral medication adherence among HIV-positive adults accessing highly active antiretroviral therapy (HAART) in British Columbia, Canada. O'Neil CR; Palmer AK; Coulter S; O'Brien N; Shen A; Zhang W; Montaner JS; Hogg RS J Int Assoc Physicians AIDS Care (Chic); 2012; 11(2):134-41. PubMed ID: 22318879 [TBL] [Abstract][Full Text] [Related]
36. Outpatient patterns of care and longitudinal intensity of antiretroviral therapy for HIV-infected drug users. Laine C; Hauck WW; Turner BJ Med Care; 2002 Oct; 40(10):976-95. PubMed ID: 12395030 [TBL] [Abstract][Full Text] [Related]
37. HAART receipt and viral suppression among HIV-infected patients with co-occurring mental illness and illicit drug use. Chander G; Himelhoch S; Fleishman JA; Hellinger J; Gaist P; Moore RD; Gebo KA AIDS Care; 2009 May; 21(5):655-63. PubMed ID: 19444675 [TBL] [Abstract][Full Text] [Related]
38. Antiretroviral adherence and HIV treatment outcomes among HIV/HCV co-infected injection drug users: the role of methadone maintenance therapy. Palepu A; Tyndall MW; Joy R; Kerr T; Wood E; Press N; Hogg RS; Montaner JS Drug Alcohol Depend; 2006 Sep; 84(2):188-94. PubMed ID: 16542797 [TBL] [Abstract][Full Text] [Related]
39. Nonadherence to antiretroviral therapy among a community with endemic rates of injection drug use. Shannon K; Kerr T; Lai C; Ishida T; Wood E; Montaner JS; Hogg RS; Tyndall MW J Int Assoc Physicians AIDS Care (Chic); 2005 Jul; 4(3):66-72. PubMed ID: 16867974 [TBL] [Abstract][Full Text] [Related]
40. Impact of active drug use on antiretroviral therapy adherence and viral suppression in HIV-infected drug users. Arnsten JH; Demas PA; Grant RW; Gourevitch MN; Farzadegan H; Howard AA; Schoenbaum EE J Gen Intern Med; 2002 May; 17(5):377-81. PubMed ID: 12047736 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]